Top Markets
Coin of the day
Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc.

6838
株式のランク #20889
Formosa Pharmaceuticals, Inc., a biopharmaceutical firm situated in Taipei... Formosa Pharmaceuticals, Inc., a biopharmaceutical firm situated in Taipei City, Taiwan, is actively engaged in both late-preclinical and early clinical development stages. Its core focus lies in pioneering therapeutic candidates across ophthalmology, oncology, and anti-infective domains. Among its key investigational assets is APP13007, an ophthalmic nanosuspension, currently progressing through Phase III trials for managing post-surgical discomfort and inflammation of the eye. The company's portfolio also encompasses TSY-0110, designed as an antibody-drug conjugate, and TSY-0210, an antibiotic targeting resilient drug-resistant infections. Further compounds under development include APP13002, a topical antibiotic intended for ocular infections like blepharitis, and MPT0E028, a novel pan-histone deacetylase inhibitor being explored for solid malignancies such as hepatomas and colorectal cancer, in addition to lung fibrosis. Additionally, Formosa Pharmaceuticals maintains a collaborative partnership with Eyenovia, Inc., dedicated to advancing innovative ophthalmic treatments. Established in 2010, the company is headquartered in Taiwan's capital.
株価
$0.79338575
最終同期: 2026-07-28
時価総額
$119.78M
変化(1日)
2.67%
変化(1年)
-27.61%
TW
取引 Formosa Pharmaceuticals, Inc. (6838)

カテゴリー

Formosa Pharmaceuticals, Inc.(6838)の利益
2026 時点の利益 TTM: 0
Formosa Pharmaceuticals, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Formosa Pharmaceuticals, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH